Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.

Companies must evolve to stay relevant in the pharmaceutical industry. Teva Pharmaceutical Industries (NYSE: TEVA) is in the midst of its own transformation, from making generic drugs and biosimilars to novel drugs that are beginning to deliver growth and profits that are catching Wall Street's eye.Every single Wall Street analyst polled by CNN Business currently has a buy rating on the pharmaceutical stock. Based on 12-month price targets, Teva could have anywhere from 28% to 60% upside from its current price, according to the analysts.It seems like a bold call, considering the broader stock market has left the stock in the dust. Teva is down 40% over the past decade. But sometimes, these comeback stories produce the biggest returns. Here's why Wall Street analysts are right to be bullish about the stock right now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool